Neuromodulators provide a rational, mechanism-based treatment option for FD and GP, and a symptom-oriented approach may optimize patient outcomes; although high-quality, subtype-specific trials are needed to strengthen the evidence base.
Hanna-Jairala et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: